title: Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients.
abstract: To determine the impact of adjuvant treatment with tamoxifen and aromatase inhibitors (AI) on the survival of men with breast cancer. We analyzed 257 male patients with hormone-receptor-positive breast cancer from numerous German population-based cancer registries treated with tamoxifen (N = 207) or aromatase inhibitors (N = 50). The median follow-up was 42.2 (range 2-115) months. Median age at diagnosis was 68 (range 36-91) years. Thirty-seven (17.9 %) patients treated with tamoxifen and 16 (32.0 %) patients treated with AI died (log rank p = 0.007). After the adjustment for the patient's age, tumor size, node status, and tumor grading, the AI treatment was linked to a 1.5-fold increase in risk of mortality compared to tamoxifen (HR 1.55; 95 % CI: 1.13-2.13; p = 0.007). The overall survival in male breast cancer was significantly better after adjuvant treatment with tamoxifen compared to an aromatase inhibitor. Tamoxifen should be considered as the treatment of choice for hormone-receptor-positive male breast cancer.
authors.affiliation: University Women's Clinic, Otto-von-Guericke University, Gerhart-Hauptmann Str. 35, 39108, Magdeburg, Germany. holm.eggemann@med.ovgu.de
authors.forename: Holm
authors.initials: H
authors.lastname: Eggemann
authors.forename: Atanas
authors.initials: A
authors.lastname: Ignatov
authors.forename: Bobbie J
authors.initials: BJ
authors.lastname: Smith
authors.forename: Udo
authors.initials: U
authors.lastname: Altmann
authors.forename: Gunter
authors.initials: G
authors.lastname: von Minckwitz
authors.forename: Freidrich W
authors.initials: FW
authors.lastname: Röhl
authors.forename: Mark
authors.initials: M
authors.lastname: Jahn
authors.forename: Serban-Dan
authors.initials: SD
authors.lastname: Costa
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D047072:Aromatase Inhibitors / Q000627:therapeutic use*; D018567:Breast Neoplasms, Male / Q000188:drug therapy* / Q000378:metabolism / Q000401:mortality* / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D005500:Follow-Up Studies; D005858:Germany; D006801:Humans; D008297:Male; D008875:Middle Aged; D011960:Receptors, Estrogen / Q000378:metabolism; D013629:Tamoxifen / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D011960:Receptors, Estrogen; D013629:Tamoxifen